Desmoda: The latest US FDA-approved oral desmopressin solution for all age groups.
4 affiliations
- 1Department of Anesthesia and Critical Care, All India Institute of Medical Science, Rishikesh, Uttarakhand, India.
- 2Department of Trauma and Emergency, All India Institute of Medical Science, Jodhpur, Rajasthan, India.
- 3Department of Anesthesia and Critical Care, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, India.
- 4Department of Pediatrics, All India Institute of Medical Science, Jodhpur, Rajasthan, India.
Abstract
Central diabetes insipidus (CDI) is an uncommon condition characterized by deficient vasopressin secretion, resulting in polyuria, polydipsia, and the potential for dehydration and electrolyte disturbances. Desmopressin, a synthetic form of vasopressin, remains the cornerstone of treatment. Desmoda, an oral liquid formulation of desmopressin approved by the United States Food and Drug Administration, provides a novel, ready-to-use option appropriate for all age demographics, especially infants and individuals with dysphagia. It facilitates accurate, weight-based dosing without requiring tablet handling or refrigeration. Desmoda signifies significant progress in CDI care; however, caution is warranted regarding hyponatremia and its use in patients with renal impairment.
Related
- Acute colonic pseudo-obstruction with transient failure of oral desmopressin in adipsic arginine vasopressin deficiency.
- Reduction of hemorrhagic complications after non-focal renal biopsy with pre-procedure desmopressin administration
- Latest findings on complications following trans- catheter aortic valve replacement: A literature review.
- Lighting up cancer: latest discoveries in ruthenium(ii) polypyridyl complexes for anticancer photodynamic therapy.
- Point-of-care ultrasound in obstetrics and gynecology: latest advancements and evolution.
BibTeX
@article{chittoria2026desmoda,
title = {{Desmoda: The latest US FDA-approved oral desmopressin solution for all age groups.}},
author = {Konica Chittoria and Ankur Sharma and Arun Mukesh and Varuna Vyas},
journal = {Saudi journal of anaesthesia},
year = {2026},
month = oct,
doi = {10.4103/sja.sja_509_26},
url = {https://europepmc.org/article/MED/42960364},
note = {CC BY-NC-SA},
}
RIS
TY - JOUR
TI - Desmoda: The latest US FDA-approved oral desmopressin solution for all age groups.
AU - Konica Chittoria
AU - Ankur Sharma
AU - Arun Mukesh
AU - Varuna Vyas
PY - 2026
DA - 2026/10/01
JO - Saudi journal of anaesthesia
DO - 10.4103/sja.sja_509_26
UR - https://europepmc.org/article/MED/42960364
AB - Central diabetes insipidus (CDI) is an uncommon condition characterized by deficient vasopressin secretion, resulting in polyuria, polydipsia, and the potential for dehydration and electrolyte disturbances. Desmopressin, a synthetic form of vasopressin, remains the cornerstone of treatment. Desmoda, an oral liquid formulation of desmopressin approved by the United States Food and Drug Administration, provides a novel, ready-to-use option appropriate for all age demographics, especially infants and individuals with dysphagia. It facilitates accurate, weight-based dosing without requiring tablet handling or refrigeration. Desmoda signifies significant progress in CDI care; however, caution is warranted regarding hyponatremia and its use in patients with renal impairment.
SN - 1658-354X
SN - 0975-3125
ER -